Premium
P3‐373: Mild cognitive disorder and depression: Treatment with association between galantamine and escitalopram
Author(s) -
Zarra Julio,
Schmidt Luisa
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.1598
Subject(s) - escitalopram , galantamine , depression (economics) , psychology , cognition , psychiatry , comorbidity , clinical psychology , disease , medicine , dementia , donepezil , antidepressant , anxiety , macroeconomics , economics
Background: During the past decade, there has been a growing interest in the predementia phase of these conditions because of suggestions that we may be able to identify the earliest clinical features of these illnesses before functional impairment is evident. Toward this end, the construct of mild cognitive impairment (MCI) has evolved to capture this predementia phase of cognitive dysfunction.Most investigators believe that if we wait for functional impairment and perhaps even mild cognitive symptoms to emerge, it may be too late to treat the underlying disease process. We would like to be able to prevent or postpone the disease process by intervening early. As such, the construct of MCI serves a useful purpose as a clinical stage in which meaningful interventions can take place. MCI may be an intermediate step on theway to primary prevention, but it remains important for formulating research hypotheses. To evaluate the efficacy of galantamine and escitalopram association in patients with Mild Cognitive Disorder and Depression. So there is a possible relation between the deficit in executive and cognitive cerebral function and depression or relation between the serotonin system and cholinergic system in relation with disease comorbidity cognitive-depression.To evaluate the therapeutic response in patients with comorbility between mild cognitive disorder and depression in treatment with galantamine with escitalopram and the two drugs associated. Methods: A group of 705 patients with symptoms of mild cognitive disorder and depression (DSM IV-TR) were separated in 3 groups of 235 patients. Each group received different treatment in 12 months: Group 1: galantamine 16 mg/ day.Group 2: escitalopram 10 mg/day.Group 3: Both drugs, same dose. Results: The therapeutic response evaluated in HAM-D, M.A.D.R.S., M.M.S.E. and G.C.I. scores during 12 months. In the third group who received the two drugs associated, had much better response than the others and “brain enhancer.”Conclusions: The group who received the association of the cholinergic agent galantamine with antidepressant escitalopram had a relevant satisfactory therapeutic response: the best result, so there is a possible relation between the deficit in cholinergic systems and depression. Discussion: Could be cerebral cholinergic systems deficit a generator of depressive disorder?